<DOC>
	<DOCNO>NCT02650375</DOCNO>
	<brief_summary>This open-label , multicenter study design assess safety , tolerability , preliminary efficacy pharmacokinetics Metatinib Tromethamine tablet patient advance metastatic gastric cancer , liver cancer , colorectal cancer , con squamous NSCLC . Patients receive Metatinib orally 200mg daily ( QD ) 100mg twice daily ( BID ) disease progression unacceptable toxicity occur . The study determine whether MET gene mutation , amplification , well MET protein overexpression tumor tissue correlate treatment efficacy clinical outcome . The potential PD biomarker Metatinib also explore .</brief_summary>
	<brief_title>Study Metatinib Tromethamine Tablet</brief_title>
	<detailed_description />
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<criteria>Patients advance metastatic gastric cancer colorectal cancer progress secondline therapy treatment protocol , patient advance metastatic hepatocellular carcinoma progress firstline chemotherapy , interventional therapy target therapy shall verify histology cytology ; patient advance metastatic nonsquamous nonsmall cell lung cancer operate fail firstline therapy shall verify histology cytology ; MET gene amplification protein overexpression ( IHC ≥2+） , exon14 skip ; At least one measurable lesion ( RECIST 1.1 ) ; At least 4 week last chemotherapy , radiotherapy antitumor biological product treatment ; least 8 week last antitumor antibody product treatment ; least 6 week last dose nitrosourea , mitomycin C doxorubicin ; At least 4 week major surgery trauma , wound fully heal ; least 1 week minor surgery trauma ( i.e . tissue biopsy fine needle aspiration ) ; Toxicity previous treatment restore ≤ grade 1 , baseline irreversible ( NCI CTC4.0 ) ; ECOG performance status 01 ; Life expectancy ≥3 month ; Adequate hematologic function : ANC≥1.5×10^9 /L , HB≥90g/L ( blood transfusion allow ) , PLT≥100×10^9/L ; Adequate hepatic function : ALT≤3×ULN , AST≤3×ULN , TBIL≤2×ULN ( patient liver metastasis liver cancer ALT≤5×ULN , AST≤5×ULN , TBIL≤2×ULN ) , ChildPugh score≤7 ; Adequate renal function : uric acid＜500μmol/L , creatinine＜1.7mg/dL , proteinuria≤2＋or≤2g/24h , GFR≥60 ml/min/1.73m^2 ; PTINR/APTT≤1.5×ULN , Serum sodium , potassium , calcium , magnesium level ≤1×ULN ( NCICTC 4.0 ) ; Patients sign write informed consent ; Willingness capability comply protocol requirement well communicate investigator . Severe , uncontrolled medical disorder active infection , include limited HIV antibody positive , active tuberculosis , HBV DNA copies＞10^3/ml ; Subjects know suspect brain metastasis ; Patients must receive chemotherapy , target therapy , hormone therapy , immunotherapy , radiotherapy ( except palliative local radiation ) traditional Chinese medicine treatment cancer study ; Previously receive VEGF/VEGFR smallmolecule inhibitor antibody therapy , include limited Bevacizumab , Ramucirumab , Aflibercept ; Previously receive HGF/cMet smallmolecule inhibitor antibody therapy , include limited Crizotinib , Cabozantinib , Volitinib , Capmatinib ( INC280 ) , BPI9016M ; Imaging show involvement major blood vessel nerve tumor ; Uncontrolled hypertension ( systolic blood pressure＞150mmHg and/or diastolic blood pressure＞100mmHg treatment ) ; LVEF＜50 % ; Apparent heart disease , include congestive heart failure ( NYHA IIIIV ) , history myocardial infarction , uncontrolled angina within 6 month prior enrollment ; Arrhythmias need treat , include atrial fibrillation , supraventricular tachycardia , ventricular tachycardia ventricular fibrillation ; ECG abnormality confirm , include QT interval prolongation ( males＞450msec , females＞470 msec ) ; History hemorrhagic thrombotic event within 6 month enrollment , i.e . cerebrovascular accident ( include TIA ) , pulmonary embolism , spontaneous hemorrhage tumor ; Patients need surgery within 28 day , expect require surgery within 28 day last dose ; Uncontrolled cavity effusion , large amount pleural effusion ascites ; Gastrointestinal illness ( i.e. , uncontrolled diarrhea malabsorption ) screening within 3 month may affect drug absorption ; History suspicious sign gastrointestinal perforation ; Concomitant medication may affect drug metabolism ( i.e . strong CYP3A4 inhibitor inducer ) ; Pregnant lactate woman ; Subjects childbearing refuse use medically acceptable method contraception 3 month last dose ; Participate clinical trial within 4 week prior enrollment ; The investigator consider patient suitable trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>